Real-World Comparison of Bezlotoxumab to Standard of Care Therapy for Prevention of Recurrent Clostridioides difficile Infection in Patients at High Risk for Recurrence

Article Immunology

Efficacy of Bezlotoxumab in Trial Participants Infected With Clostridioides difficile Strain BI Associated With Poor Outcomes

Stuart Johnson et al.

Summary: In the MODIFY I/II trials, infection with BI strains of C. difficile was associated with poor outcomes. Bezlotoxumab treatment was effective in both BI and non-BI subpopulations.

CLINICAL INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Gastroenterology & Hepatology

ACG Clinical Guidelines: Prevention, Diagnosis, and Treatment of Clostridioides difficile Infections

Colleen R. Kelly et al.

Summary: This article discusses the causes and management of Clostridioides difficile infection, as well as the official practice recommendations of the American College of Gastroenterology. The guidelines were evaluated using the Grading of Recommendations Assessment, Development, and Evaluation process.

AMERICAN JOURNAL OF GASTROENTEROLOGY (2021)

添加到收藏夹

Article Infectious Diseases

Cost-effectiveness of bezlotoxumab and fidaxomicin for initial Clostridioides difficile infection

Jiahe Chen et al.

Summary: The study evaluated the cost-effectiveness of fidaxomicin and bezlotoxumab in treating initial CDI compared to standard therapy with oral vancomycin. Extended-pulsed fidaxomicin was found to be the most cost-effective treatment, while standard fidaxomicin was more effective than vancomycin and the bezlotoxumab-containing regimen required higher costs.

CLINICAL MICROBIOLOGY AND INFECTION (2021)

添加到收藏夹

Article Immunology

Clinical Practice Guideline by the Infectious Diseases Society of America (IDSA) and Society for Healthcare Epidemiology of America (SHEA): 2021 Focused Update Guidelines on Management of Clostridioides difficile Infection in Adults

Stuart Johnson et al.

Summary: This guideline offers focused updates on the management of Clostridioides difficile infection (CDI) in adults, specifically addressing the use of fidaxomicin and bezlotoxumab. Recommendations are based on evidence from systematic literature reviews and rated using the GRADE approach.

CLINICAL INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Immunology

Effectiveness of Bezlotoxumab for Prevention of Recurrent Clostridioides difficile Infection Among Transplant Recipients

Tanner M. Johnson et al.

Summary: The study demonstrates that in a cohort primarily composed of SOT recipients, patients receiving bezlotoxumab plus standard of care had a lower incidence of recurrent CDI at 90 days and showed good tolerability. Further larger, prospective trials are needed to confirm these findings among SOT and HCT populations.

OPEN FORUM INFECTIOUS DISEASES (2021)

添加到收藏夹

Article Immunology